Biosimilar Monoclonal Antibodies (mAbs) Market by Application and Geography- Forecast and Analysis 2021-2025

  • Published: Jul 2021
  • Pages: 120
  • SKU: IRTNTR41616

Purchase this report now and if we publish a new version within 90 days, we will send you a free copy.

Safe and Secure SSL Encrypted
  • 2500.00
  • USD

 Biosimilar Monoclonal Antibodies (mAbs) Market - 2021-2025

The biosimilar monoclonal antibodies (mAbs) market size is expected to reach a value of USD 3.48 billion, at a CAGR of 14.05%, during 2021-2025. This research study helps in a deep understanding of the underlying forces driving the market growth and current and potential target customers across segmentations. According to our comprehensive survey, factors such as the increasing prevalence of chronic diseases are projected to significantly support market growth during the forecast period. View our sample report for insights on the latest trends and challenges that will have a far-reaching effect on the market growth.

Biosimilar monoclonal antibodies (mAbs) Market Size

To Unlock the Biosimilar monoclonal antibodies (mAbs) Market Size for 2021 and Other Important Statistics Wait no Longer!

Complete the Payment and Get this Report Within a Minute!

Biosimilar Monoclonal Antibodies (mAbs) Market Segments

Get actionable insights on the biosimilar monoclonal antibodies market segments to generate successful ROIs and focus your business strategy efforts where they are most likely to be effective. Navigate through market segmentation by application (cancer and non-cancer) and geography (North America, Europe, Asia, and ROW) in this biosimilar monoclonal antibodies market report to pursue growth opportunities. 

Furthermore, given the current pandemic situation and its significant effect on industries, it is essential to understand the vulnerable market segments and recovery scope. Our market research experts have evaluated the impact of COVID-19 across market segments for our clients to understand the long-term business implications and foresee opportunities to strengthen market foothold. Want a thorough qualitative and quantitative analysis on the post-pandemic biosimilar monoclonal antibodies market predictions on-demand changes for 2021-2025? You can buy the report now with one easy click.

Biosimilar Monoclonal Antibodies (mAbs) Market Vendors and Competitive Analysis

The biosimilar mAbs market is concentrated and the vendors are deploying growth strategies such as increasing their product offerings and geographical reach to gain a competitive advantage. Find out about other well-thought-out business planning approaches of key players from our sample report.

The biosimilar monoclonal antibodies market share report highlights the repercussions of the effects of the pandemic across regions and segments, and the entire value chain. To make the most of the emerging opportunities and recover from adverse COVID-19 shock, the market vendors should focus more on leveraging change in consumer behavior and growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. Click here to get COVID-19 impact update.

For detailed insights on complete key vendor profiles buy the full biosimilar monoclonal antibodies market forecast report. The profiles include particulars on the production, sustainability, prospects of the leading companies, and other crucial vendor landscape analysis.

Biosimilar monoclonal antibodies (mAbs) Market Vendors

Biosimilar Monoclonal Antibodies (mAbs) Market - Region Opportunities 2021-2025

45% of the biosimilar monoclonal antibodies market growth will originate from North America during the forecast period. The US is a key market for biosimilar monoclonal antibodies in North America. To unlock exclusive information on potential business locations and understand the demographics of current and prospective customers buy the report now!

Biosimilar monoclonal antibodies (mAbs) Market Share by Geography

North America has been exhibiting a significant growth rate for biosimilar monoclonal antibodies market vendors. Factors such as the strong prevalence of chronic diseases, increasing patent expiration, and the growing approval of biosimilar mAbs are accelerating the biosimilar mAbs market growth in North America. To view our in-depth analytical review on the micro and macroeconomic factors impacting businesses in the regions click here.

However, the biosimilar monoclonal antibodies market share growth rate in North America will be slower than the growth of the market in other regions. To garner further competitive intelligence and regional opportunities in store for vendors, view our sample report.

Biosimilar Monoclonal Antibodies (mAbs) Market Insights by Application

Biosimilar monoclonal antibodies (mAbs) Market Share by Application

To gain further insights on the market contribution of various segments Request for a FREE Sample!

According to our market segmentation data analysis, the cancer segment is expected to be a significant contributor to the growth of the biosimilar monoclonal antibodies market share during the forecast period. Several vendors are developing biosimilar mAbs as they are cost-effective treatments for cancer. An increasing number of biosimilar mAbs gaining approval will drive the market growth in the cancer segment during the forecast period. This report provides an accurate prediction of the revenue share of all the segments to the growth of the biosimilar mAbs market size.

From the biosimilar monoclonal antibodies market segmentation insights, players can achieve maximum market response by understanding the target consumers. The analytical data on the segmentation will allow vendors to position their services and products among the right audiences and gain significant exposure and growth. Also, get updated actionable market insights on post COVID-19 impact on each segment.

Biosimilar Monoclonal Antibodies (mAbs) Market Drivers & Trends

Even if the success rate of a business is higher, every factor, including challenges, influencing any market growth needs to be considered to mitigate potential risks at an earlier development stage. One of the key factors impeding the biosimilar mAbs market growth is the presence of stringent regulatory policies. Purchase our express report to get exhaustive insights on the key industry trends, drivers, and challenges, which will help companies evaluate and build growth strategies.

The increasing prevalence of chronic diseases will fuel the growth of the biosimilar monoclonal antibodies market size. The increasing prevalence of chronic diseases globally has become a serious public health concern. Chronic diseases such as cancer and autoimmune diseases can lead to death if left untreated. The common types of cancer are breast cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, lung and bronchus cancer, bladder cancer, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, non-Hodgkin lymphoma, and liver cancer. As the treatment costs of the above-mentioned diseases are high, the development of cost-effective therapeutics becomes imperative. As biosimilar mAbs are a cost-effective option, their demand from patients is increasing. 

Technavio research analysts have done an in-depth analysis of the biosimilar monoclonal antibodies market trends, drivers, and challenges in terms of their long-term and short-term effects. This data will help players map their growth prospects across key and emerging markets.


market _name Report

Need a Customized Report? Get in touch

Biosimilar Monoclonal Antibodies (mAbs) Market Report Outlook

  • CAGR of the market during the forecast period 2021-2025
  • Detailed information on factors that will drive biosimilar monoclonal antibodies market growth during the next five years
  • Precise estimation of the biosimilar monoclonal antibodies market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the biosimilar monoclonal antibodies market across North America, Europe, Asia, and ROW
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of biosimilar mAbs market vendors

Buy the Biosimilar Monoclonal Antibodies (mAbs) Market report now to reimage your business strategies!


Read More Read Less

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.


Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases


Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts



  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis


  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your FREE sample now!
The biosimilar monoclonal antibodies (mabs) market growth will increase by $8.65 billion during 2019-2024.
The biosimilar monoclonal antibodies (mabs) market is expected to grow at a CAGR of 30.17% during 2019-2024.
Technavio has segmented the biosimilar monoclonal antibodies (mabs) market by application (Cancer and Non-cancer) and geographic (North America, Europe, and Asia).
Amgen Inc., BIOCAD, Biocon Ltd., BioXpress Therapeutics SA, Boehringer Ingelheim International GmbH, Celltrion Inc., Coherus BioSciences Inc., Intas Pharmaceuticals Ltd., Novartis AG, Pfizer Inc. are a few of the key vendors in the biosimilar monoclonal antibodies (mabs) market.
North America will register the highest growth rate of 54.86% among the other regions. Therefore, the biosimilar monoclonal antibodies (mabs) market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
The key factors driving the biosimilar monoclonal antibodies (mabs) market growth are:
  • Increase in the number of expiring patents of blockbuster mAbs
  • Growing popularity of smart alternators
The biosimilar monoclonal antibodies (mabs) market vendors should focus on grabbing business opportunities from the cancer segment as it accounted for the largest market share in the base year.
Safe and Secure SSL Encrypted

Single User:

2500 USD

Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase

Technavio's SUBSCRIPTION platform

Register for a free trial today and gain instant access to 17,000+ market research reports.


Enquire Before Buying
  1. Home
  2. Health Care
  3. Published Report

What other custmores say

17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>